Therapeutic Radionuclides: Biophysical and Radiobiologic Principles
Section snippets
Energetic Particles
In general, the distribution of therapeutic radiopharmaceuticals within a targeted solid tumor is not homogeneous. This is mainly a result of (1) the inability of the radiolabeled molecules to penetrate uniformly dissimilar regions within a solid tumor mass; (2 the high interstitial pressure of solid tumors; and/or (3) differences in the binding-site densities of tumor cells. In the case of radiopharmaceuticals labeled with energetic alpha-particle and beta-particle emitters (range of emitted
Radiobiology
The deposition of energy by ionizing radiation in mammalian cells is a random process. The absorption of energy in such cells can induce certain molecular modifications that may lead to cell death. Although this process is stochastic in nature, the death of a few cells within a tissue or an organ will not have, in general, a significant effect on function. However, as the dose increases, more cells will die with the eventual impairment of tissue/organ function.8
Alpha-Particle Emitters
The application of alpha-particle-emitting radionuclides as targeted therapeutic agents continues to be of interest. When such radionuclides are selectively accumulated in the targeted tissues (eg, tumors), their decay should result in highly localized energy deposition in the tumor cells and minimal irradiation of surrounding normal host tissues.22, 23
The investigation of the therapeutic potential of alpha-particle emitters has focused mainly on astatine-211 (211At), bismuth-212 (212Bi),
Conclusions
The increase in our understanding of the dosimetry and the therapeutic potential of various modes of radioactive decay has heightened the possibility of using radiolabeled carriers in cancer therapy. Moreover, as a consequence of the great strides in genomics, the development of more precise targeting molecules is at hand. Further progress in the field of targeted radionuclide therapy is being made by the judicious design of radiolabeled molecules that match the physical and chemical
References (48)
- et al.
Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs
Eur J Cancer Clin Oncol
(1987) - et al.
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Lancet
(1998) - et al.
5-[123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model
Int J Radiat Oncol Biol Phys
(1991) - et al.
Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211
Radiat Res
(1998) - et al.
Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments
J Nucl Med
(1994) The amazing world of Auger electrons
Int J Radiat Biol
(2004)Absorption of 20-eV to 50,000-eV electron beams in air and plastic
Radiat Res
(1969)- et al.
Radiotoxicity of 75Se and 35S: theory and application to a cellular model
Radiat Res
(1980) - et al.
Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells
Radiat Res
(1982) - et al.
Intracellular localisation of Auger electron emitters: Biophysical dosimetry
Radiat Prot Dosimetry
(1985)
Does nonuniformity of dose have implications for radiation protection?
J Nucl Med
LET dependence of linear and quadratic terms in dose-response relationships for cellular damage: Correlations with the dimensions and structures of biological targets
Radiat Prot Dosimetry
Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from α-particle irradiated to nonirradiated cells
Proc Natl Acad Sci USA
α particles initiate biological production of superoxide anions and hydrogen peroxide in human cells
Cancer Res
Alpha particles induce the production of interleukin-8 by human cells
Radiat Res
Factors underlying the cell growth-related bystander responses to α particles
Cancer Res
Inhibitory and stimulatory bystander effects are differentially induced by iodine-125 and iodine-123
Radiat Res
MIRD continuing education: Bystander and low–dose-rate effects: Are these relevant to radionuclide therapy?
J Nucl Med
Bystander effect produced by radiolabeled tumor cells in vivo.
Proc Natl Acad Sci USA
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and Auger electron–emitting radionuclides
J Nucl Med
Nonuniformity of tumor dose in radioimmunotherapy
J Nucl Med
Microdosimetry in radioimmunotherapy
Radiat Prot Dosimetry
International Commission on Radiation Units and Measurements: Absorbed-Dose Specification in Nuclear Medicine, Report 67
J ICRU
The impact of tumor cell proliferation in radioimmunotherapy
Cancer
Cited by (200)
Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: Application to <sup>177</sup>Lu-PSMA therapy of prostate cancer
2024, Computer Methods and Programs in BiomedicineNext generation radiotheranostics promoting precision medicine
2023, Annals of OncologyRadioimmunoconjugates in the age of modern immuno-oncology
2022, Life SciencesPosition paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
2024, EJNMMI Radiopharmacy and Chemistry
Supported by NIH 5 R01 CA015523.